Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part B Demonstration Project Guidance Expected In "Weeks" – CMS

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA Commissioner McClellan's confirmation as CMS administrator has delayed the start of the demonstration project. CMS has not made any final decisions regarding the coverage of specific drugs.

You may also be interested in...



Medicare Part B Oral Chemotherapy Demo Limited To Approved Indications

Given caps on enrollment and spending in the demonstration, off-label drug coverage would result in fewer patients receiving approved drugs for labeled indications, CMS says. The agency will discuss proposed coverage criteria during April 23 “open door forum.”

Medicare Part B Oral Chemotherapy Demo Limited To Approved Indications

Given caps on enrollment and spending in the demonstration, off-label drug coverage would result in fewer patients receiving approved drugs for labeled indications, CMS says. The agency will discuss proposed coverage criteria during April 23 “open door forum.”

Medicare Part B "Replacement" Drug Demo Should Cover Tamoxifen, Breast Cancer Group Says

The National Breast Cancer Coalition is lobbying CMS to pay for tamoxifen under a demonstration project. NBCC is seeking a broader interpretation of the statute.

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel